Do analysts rate BGM or SNGX?

Soligenix has a consensus target price of $6.00, indicating a potential upside of 1,100.00%. Given Soligenix's stronger consensus rating and higher possible upside, analysts clearly believe Soligenix is more favorable than BGM Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Soligenix 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation and earnings, BGM or SNGX?

BGM Group has higher revenue and earnings than Soligenix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BGM Group $25.10M 1.34 -$1.44M N/A N/A Soligenix $120K 61.75 -$11.08M -$1.68 N/A

Is BGM or SNGX more profitable?

BGM Group's return on equity of 0.00% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets BGM Group N/A N/A N/A Soligenix N/A -244.73% -131.22%

Do analysts recommend SNGX or MYNZ?

Soligenix presently has a consensus price target of $6.00, indicating a potential upside of 1,100.00%. Given Soligenix's stronger consensus rating and higher possible upside, equities analysts plainly believe Soligenix is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soligenix 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is SNGX or MYNZ more profitable?

Mainz Biomed's return on equity of 0.00% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Soligenix N/A -244.73% -131.22% Mainz Biomed N/A N/A N/A

Do analysts recommend PLRZ or SNGX?

Soligenix has a consensus price target of $6.00, indicating a potential upside of 1,100.00%. Given Soligenix's stronger consensus rating and higher probable upside, analysts plainly believe Soligenix is more favorable than Polyrizon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Soligenix 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, PLRZ or SNGX?

Polyrizon has higher earnings, but lower revenue than Soligenix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polyrizon N/A N/A -$3.34M N/A N/A Soligenix $120K 61.75 -$11.08M -$1.68 N/A

Is PLRZ or SNGX more profitable?

Polyrizon's return on equity of 0.00% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Polyrizon N/A N/A N/A Soligenix N/A -244.73% -131.22%

Does the media favor PLRZ or SNGX?

In the previous week, Polyrizon and Polyrizon both had 1 articles in the media. Soligenix's average media sentiment score of 1.28 beat Polyrizon's score of 0.42 indicating that Soligenix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Polyrizon 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Soligenix 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NEUP or SNGX more profitable?

Neuphoria Therapeutics' return on equity of -76.93% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Neuphoria Therapeutics N/A -76.93% -54.76% Soligenix N/A -244.73% -131.22%

Is SNGX or LSTA more profitable?

Lisata Therapeutics' return on equity of -103.54% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Soligenix N/A -244.73% -131.22% Lisata Therapeutics N/A -103.54% -83.08%

Soligenix (SNGX) Competitors

$0.50 +0.02 (+3.50%)

As of 10:33 AM Eastern

Compare

SNGX vs. BGM, MYNZ, PLRZ, NEUP, and LSTA

Should you buy Soligenix stock or one of its competitors? MarketBeat compares Soligenix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Soligenix include BGM Group (BGM), Mainz Biomed (MYNZ), Polyrizon (PLRZ), Neuphoria Therapeutics (NEUP), and Lisata Therapeutics (LSTA). These companies are all part of the "pharmaceutical products" industry.

How does Soligenix compare to BGM Group?

BGM Group (NASDAQ:BGM) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

In the previous week, Soligenix had 1 more articles in the media than BGM Group. MarketBeat recorded 1 mentions for Soligenix and 0 mentions for BGM Group. BGM Group's average media sentiment score of 1.87 beat Soligenix's score of 1.28 indicating that BGM Group is being referred to more favorably in the media.

Company	Overall Sentiment
BGM Group	Very Positive
Soligenix	Positive

BGM Group has higher revenue and earnings than Soligenix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$25.10M	1.34	-$1.44M	N/A	N/A
Soligenix	$120K	61.75	-$11.08M	-$1.68	N/A

Soligenix has a consensus target price of $6.00, indicating a potential upside of 1,100.00%. Given Soligenix's stronger consensus rating and higher possible upside, analysts clearly believe Soligenix is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Soligenix	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

3.6% of Soligenix shares are held by institutional investors. 58.7% of BGM Group shares are held by insiders. Comparatively, 3.1% of Soligenix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

BGM Group has a beta of 1.81, indicating that its stock price is 81% more volatile than the broader market. Comparatively, Soligenix has a beta of 1.84, indicating that its stock price is 84% more volatile than the broader market.

BGM Group's return on equity of 0.00% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
Soligenix	N/A	-244.73%	-131.22%

Summary

Soligenix beats BGM Group on 7 of the 13 factors compared between the two stocks.

How does Soligenix compare to Mainz Biomed?

Soligenix (NASDAQ:SNGX) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

Soligenix presently has a consensus price target of $6.00, indicating a potential upside of 1,100.00%. Given Soligenix's stronger consensus rating and higher possible upside, equities analysts plainly believe Soligenix is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Soligenix has a beta of 1.84, meaning that its share price is 84% more volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market.

Mainz Biomed's return on equity of 0.00% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	N/A	-244.73%	-131.22%
Mainz Biomed	N/A	N/A	N/A

Soligenix has higher earnings, but lower revenue than Mainz Biomed. Soligenix is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	$120K	61.75	-$11.08M	-$1.68	N/A
Mainz Biomed	$659.94K	33.77	-$21.65M	-$65.60	N/A

In the previous week, Soligenix had 1 more articles in the media than Mainz Biomed. MarketBeat recorded 1 mentions for Soligenix and 0 mentions for Mainz Biomed. Soligenix's average media sentiment score of 1.28 beat Mainz Biomed's score of 0.00 indicating that Soligenix is being referred to more favorably in the media.

Company	Overall Sentiment
Soligenix	Positive
Mainz Biomed	Neutral

3.6% of Soligenix shares are owned by institutional investors. 3.1% of Soligenix shares are owned by insiders. Comparatively, 18.2% of Mainz Biomed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Soligenix beats Mainz Biomed on 10 of the 15 factors compared between the two stocks.

How does Soligenix compare to Polyrizon?

Polyrizon (NASDAQ:PLRZ) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Polyrizon has higher earnings, but lower revenue than Soligenix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
Soligenix	$120K	61.75	-$11.08M	-$1.68	N/A

Polyrizon's return on equity of 0.00% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
Soligenix	N/A	-244.73%	-131.22%

In the previous week, Polyrizon and Polyrizon both had 1 articles in the media. Soligenix's average media sentiment score of 1.28 beat Polyrizon's score of 0.42 indicating that Soligenix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Polyrizon	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Soligenix	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Soligenix has a consensus price target of $6.00, indicating a potential upside of 1,100.00%. Given Soligenix's stronger consensus rating and higher probable upside, analysts plainly believe Soligenix is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Soligenix	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Polyrizon has a beta of -1.9, indicating that its stock price is 290% less volatile than the broader market. Comparatively, Soligenix has a beta of 1.84, indicating that its stock price is 84% more volatile than the broader market.

3.6% of Soligenix shares are owned by institutional investors. 3.1% of Soligenix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Soligenix beats Polyrizon on 8 of the 11 factors compared between the two stocks.

How does Soligenix compare to Neuphoria Therapeutics?

Neuphoria Therapeutics (NASDAQ:NEUP) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Neuphoria Therapeutics has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market. Comparatively, Soligenix has a beta of 1.84, indicating that its stock price is 84% more volatile than the broader market.

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 3.6% of Soligenix shares are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by insiders. Comparatively, 3.1% of Soligenix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Neuphoria Therapeutics has higher revenue and earnings than Soligenix. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$15.65M	1.59	-$370K	-$11.06	N/A
Soligenix	$120K	61.75	-$11.08M	-$1.68	N/A

Neuphoria Therapeutics presently has a consensus price target of $21.00, suggesting a potential upside of 357.02%. Soligenix has a consensus price target of $6.00, suggesting a potential upside of 1,100.00%. Given Soligenix's higher probable upside, analysts plainly believe Soligenix is more favorable than Neuphoria Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Soligenix	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Neuphoria Therapeutics' return on equity of -76.93% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-76.93%	-54.76%
Soligenix	N/A	-244.73%	-131.22%

In the previous week, Soligenix had 1 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 1 mentions for Soligenix and 0 mentions for Neuphoria Therapeutics. Neuphoria Therapeutics' average media sentiment score of 1.44 beat Soligenix's score of 1.28 indicating that Neuphoria Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Neuphoria Therapeutics	Positive
Soligenix	Positive

Summary

Soligenix beats Neuphoria Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Soligenix compare to Lisata Therapeutics?

Soligenix (NASDAQ:SNGX) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

Soligenix has higher earnings, but lower revenue than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	$120K	61.75	-$11.08M	-$1.68	N/A
Lisata Therapeutics	$170K	182.74	-$16.59M	-$1.86	N/A

3.6% of Soligenix shares are held by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are held by institutional investors. 3.1% of Soligenix shares are held by insiders. Comparatively, 9.6% of Lisata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Soligenix had 1 more articles in the media than Lisata Therapeutics. MarketBeat recorded 1 mentions for Soligenix and 0 mentions for Lisata Therapeutics. Soligenix's average media sentiment score of 1.28 beat Lisata Therapeutics' score of 0.93 indicating that Soligenix is being referred to more favorably in the media.

Company	Overall Sentiment
Soligenix	Positive
Lisata Therapeutics	Positive

Soligenix presently has a consensus target price of $6.00, indicating a potential upside of 1,100.00%. Lisata Therapeutics has a consensus target price of $15.00, indicating a potential upside of 339.88%. Given Soligenix's stronger consensus rating and higher probable upside, equities analysts clearly believe Soligenix is more favorable than Lisata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Soligenix has a beta of 1.84, meaning that its share price is 84% more volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

Lisata Therapeutics' return on equity of -103.54% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	N/A	-244.73%	-131.22%
Lisata Therapeutics	N/A	-103.54%	-83.08%

Summary

Soligenix beats Lisata Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Soligenix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNGX vs. The Competition

Export

Metric	Soligenix	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.48M	$3.34B	$6.42B	$12.34B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-0.30	18.27	23.80	24.23
Price / Sales	61.75	321.19	527.67	119.15
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	0.96	6.74	9.99	6.74
Net Income	-$11.08M	$24.20M	$3.56B	$337.06M
7 Day Performance	-48.59%	-2.81%	-1.18%	-0.13%
1 Month Performance	N/A	N/A	N/A	-1.62%
1 Year Performance	-73.68%	48.31%	28.52%	33.25%

Soligenix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNGX Soligenix	3.1623 of 5 stars	$0.50 +3.5%	$6.00 +1,100.0%	-75.2%	$7.48M	$120K	N/A	20	Positive News Gap Up
BGM BGM Group	1.1768 of 5 stars	$0.31 +6.8%	N/A	-97.9%	$30.33M	$25.10M	N/A	298	Positive News Gap Up
MYNZ Mainz Biomed	N/A	$3.33 -6.5%	N/A	+23.1%	$30.17M	$659.94K	N/A	30	Gap Up High Trading Volume
PLRZ Polyrizon	0.3295 of 5 stars	$16.07 +5.3%	N/A	+177.0%	$30.05M	N/A	N/A	N/A	Gap Down
NEUP Neuphoria Therapeutics	3.5519 of 5 stars	$5.41 -1.3%	$21.00 +288.2%	-31.4%	$29.21M	$15.65M	N/A	N/A	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNGX) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Soligenix (SNGX) Competitors

SNGX vs. BGM, MYNZ, PLRZ, NEUP, and LSTA

How does Soligenix compare to BGM Group?

Summary

How does Soligenix compare to Mainz Biomed?

Summary

How does Soligenix compare to Polyrizon?

Summary

How does Soligenix compare to Neuphoria Therapeutics?

Summary

How does Soligenix compare to Lisata Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNGX vs. The Competition

Soligenix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Soligenix (SNGX) Competitors

SNGX vs. BGM, MYNZ, PLRZ, NEUP, and LSTA

How does Soligenix compare to BGM Group?

Does the media favor BGM or SNGX?

Which has preferable valuation and earnings, BGM or SNGX?

Do analysts rate BGM or SNGX?

Do insiders and institutionals believe in BGM or SNGX?

Which has more risk and volatility, BGM or SNGX?

Is BGM or SNGX more profitable?

Summary

How does Soligenix compare to Mainz Biomed?

Do analysts recommend SNGX or MYNZ?

Which has more risk & volatility, SNGX or MYNZ?

Is SNGX or MYNZ more profitable?

Which has preferable earnings & valuation, SNGX or MYNZ?

Does the media prefer SNGX or MYNZ?

Do insiders & institutionals believe in SNGX or MYNZ?

Summary

How does Soligenix compare to Polyrizon?

Which has stronger earnings and valuation, PLRZ or SNGX?

Is PLRZ or SNGX more profitable?

Does the media favor PLRZ or SNGX?

Do analysts recommend PLRZ or SNGX?

Which has more volatility and risk, PLRZ or SNGX?

Do insiders & institutionals believe in PLRZ or SNGX?

Summary

How does Soligenix compare to Neuphoria Therapeutics?

Which has more volatility and risk, NEUP or SNGX?

Do insiders and institutionals hold more shares of NEUP or SNGX?

Which has higher valuation and earnings, NEUP or SNGX?

Do analysts recommend NEUP or SNGX?

Is NEUP or SNGX more profitable?

Does the media prefer NEUP or SNGX?

Summary

How does Soligenix compare to Lisata Therapeutics?

Which has preferable valuation & earnings, SNGX or LSTA?

Do institutionals & insiders hold more shares of SNGX or LSTA?

Does the media favor SNGX or LSTA?

Do analysts rate SNGX or LSTA?

Which has more volatility & risk, SNGX or LSTA?

Is SNGX or LSTA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNGX vs. The Competition

Soligenix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools